CASI Pharmaceuticals Announces CID-103 Update, Acquisition Proposal at $1.15 per Share
CASI Pharmaceuticals announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia. Initial clinical data from this study were presented at the 67th American Society of Hematology Annual Meeting and Exposition on December 7, 2025, in Orlando, Florida. Updated safety and efficacy data can be found on the CASI website here. The update includes additional safety and efficacy data based on: CID-103 at 30 mg, 150 mg, 300 mg, 600 mg and 900 mg; ~5 weeks of additional dosing / follow up for the ongoing patients in all cohorts; 3 additional patients enrolled in 900 mg cohort; 2 patients are at Week 5 of study treatment; 1 patient is at Week 3 of study treatment; 2 additional patients enrolled and one patient is in screening in 600 mg cohort; 1 patient is at Week 3 of study treatment; 1 patient is at Week 2 of study treatment. Interim Results: CID-103 demonstrated a manageable safety profile with only two Grade 3 treatment-related events and no dose limiting toxicities observed; All infusion-related reactions occurred with priming dose and are due to low grade AEs; Primary Efficacy Endpoint achieved in 12 of 15 evaluable patients; 10 of 15 evaluable patients achieved Complete Response with platelet improvement observed as early as one week post dose; Reduction of PD markers (decreased anti-platelet antibodies, immunoglobulins, NK and plasma cells) is consistent with the presumed CID-103 MOA resulting in the observed platelet response Separately, the Company announced that its board of directors received a preliminary non-binding proposal, dated January 7, 2026,which was further amended by an updated preliminary non-binding proposal dated January 9, 2026 from Dr. Wei-Wu He, to acquire all of the outstanding ordinary shares, par value $0.0001 per share, of the Company, that are not already beneficially owned by Dr. He for a proposed purchase price of $1.15 per Ordinary Share. The proposed price represents a 30% premium to the average closing price during the last 30 trading days.
Trade with 70% Backtested Accuracy
Analyst Views on CASI
About CASI
About the author
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
CASI Pharma Receives New $20 Mln Buyout Proposal For China Unit And Drug Rights
CASI Pharmaceuticals Proposal: CASI Pharmaceuticals Inc. announced that its Special Committee received an updated non-binding proposal from CEO Dr. Wei-Wu He to acquire the company's operations in China for $20 million, which includes assuming $20 million in debt and rights to certain products in Asia.
Evaluation of Proposal: The board has formed a Special Committee to evaluate this proposal and other strategic options, emphasizing that no decisions have been made yet and there is no guarantee that a definitive agreement will be reached.
Casi Pharmaceuticals files $200M mixed securities shelf
Casi Pharmaceuticals Filing: Casi Pharmaceuticals (CASI) has filed a $200 million mixed securities shelf registration, allowing them to raise capital through various types of securities.
Recent Performance and News: The company is currently facing challenges, including a license termination dispute regarding Evomela® and mixed financial results for Q3 2024, with an EPS of 55 cents compared to a loss of 35 cents last year.
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
CASI Pharma Receives New $20 Mln Buyout Proposal For China Unit And Drug Rights
CASI Pharmaceuticals Proposal: CASI Pharmaceuticals Inc. announced that its Special Committee received an updated non-binding proposal from CEO Dr. Wei-Wu He to acquire the company's operations in China for $20 million, which includes assuming $20 million in debt and rights to certain products in Asia.
Evaluation of Proposal: The board has formed a Special Committee to evaluate this proposal and other strategic options, emphasizing that no decisions have been made yet and there is no guarantee that a definitive agreement will be reached.
Casi Pharmaceuticals files $200M mixed securities shelf
Casi Pharmaceuticals Filing: Casi Pharmaceuticals (CASI) has filed a $200 million mixed securities shelf registration, allowing them to raise capital through various types of securities.
Recent Performance and News: The company is currently facing challenges, including a license termination dispute regarding Evomela® and mixed financial results for Q3 2024, with an EPS of 55 cents compared to a loss of 35 cents last year.
